Botanix Pharmaceuticals Ltd
ASX:BOT
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.14
0.435
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Botanix Pharmaceuticals Ltd
Botanix Pharmaceuticals Ltd
Capital Expenditures
Botanix Pharmaceuticals Ltd
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Capital Expenditures
-AU$18m
|
CAGR 3-Years
-1 195%
|
CAGR 5-Years
-323%
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Capital Expenditures
-AU$20.9m
|
CAGR 3-Years
6%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Capital Expenditures
-AU$25k
|
CAGR 3-Years
-46%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
5%
|
|
|
Probiotec Ltd
ASX:PBP
|
Capital Expenditures
-AU$10.8m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-5%
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Capital Expenditures
-AU$583k
|
CAGR 3-Years
-64%
|
CAGR 5-Years
-72%
|
CAGR 10-Years
2%
|
|
|
Arovella Therapeutics Ltd
ASX:ALA
|
Capital Expenditures
-AU$129.3k
|
CAGR 3-Years
37%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
Botanix Pharmaceuticals Ltd
Glance View
Botanix Pharmaceuticals Ltd. engages in the development of therapeutics for the treatment of skin diseases. The company is headquartered in Perth, Western Australia. The firm's product pipelines are based on drug delivery technology known as Permetrex. Its product pipeline consists of three clinical programs, which are using synthetic cannabidiol in the topical treatment of serious skin diseases and for antimicrobial applications. Its product pipeline includes BTX 1503 Gel, BTX 1702 Solution and BTX 1801 Ointment. Its BTX1503 Gel is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Its BTX 1702 Solution is used for the treatment of papulopustular rosacea. Its BTX 1801 Ointment is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus (MRSA). The firm also has a chemistry program to identify, synthesize and test chemical entities that are related to naturally occurring cannabinoids.
See Also
What is Botanix Pharmaceuticals Ltd's Capital Expenditures?
Capital Expenditures
-18m
AUD
Based on the financial report for Jun 30, 2024, Botanix Pharmaceuticals Ltd's Capital Expenditures amounts to -18m AUD.
What is Botanix Pharmaceuticals Ltd's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-323%
Over the last year, the Capital Expenditures growth was -155%. The average annual Capital Expenditures growth rates for Botanix Pharmaceuticals Ltd have been -1 195% over the past three years , -323% over the past five years .
You don't have any saved screeners yet
